ARTICLE | Clinical News
Pharmos starts Phase III brain injury study
January 10, 2001 8:00 AM UTC
PARS began the European portion of its Phase III study of dexanabinol synthetic non-psychotropic cannabinoid analog to treat severe traumatic brain injury. The U.S. arm of the trial is expected to beg...